• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Press Release: MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind System

Press Release: MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind System

July 10, 2014 By MassDevice

Press Release: MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind System

Irvington, NY — MELA Sciences, Inc. (NASDAQ: MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind system as an aid in the detection of melanoma.  The company has submitted an application for a Current Procedural Terminology (CPT) code, which is necessary for Medicare Part B reimbursement by the Centers for Medicare and Medicaid Services (CMS).  MSDSLA could be eligible for payment under Part B as early as January 1, 2016.  The company will also commence efforts to obtain reimbursement from private insurance companies as the CMS review process proceeds.

CPT codes are determined by the American Medical Association (AMA) under a rigorous review process.  Currently, there is no CPT code available for the MelaFind process.  The AMA’s CPT Editorial Panel ultimately decides whether to accept a new code, and will refer a new code to the AMA’s Relative Value Scale Update Committee (RUC). The RUC determines the relative value of physician work within the procedure or service and makes a recommendation to CMS.  CMS then establishes the appropriate reimbursement level for the service.  Obtaining Medicare reimbursement is critical in order to secure reimbursement from other public and private insurers.

Rose Crane, President and CEO of MELA Sciences, commented, "Our CPT application is the first concrete step in achieving our goal of obtaining insurance reimbursement for physician use of the MelaFind system.  MelaFind’s ability to improve diagnostic accuracy without increasing the number of biopsies, as demonstrated with the data presented at the 2014 American Dermoscopy Association Meeting is very meaningful to both patients and physicians and ultimately can save costs in the healthcare system.  We believe our application makes a compelling argument in favor of receiving the CPT code and for obtaining reimbursement from CMS."

The poster presentation at the meeting measured the impact of the MelaFind information on a dermatologist’s decision to biopsy high risk lesions.   The biopsy sensitivity of dermatologists (a measure of the percentage of lesions correctly identified as melanoma) increased from 68% to 89% with the addition of the MelaFind probability information, and specificity (a measure of the percentage of lesions correctly identified as not being melanoma) increased from 39% to 54%. The average percentage of benign lesions selected for biopsy decreased from 61% to 46%.  The p-value in all three measurements was statistically significant at p<0.001. There was a non-significant change in the percentage of total lesions selected for biopsy.

About MelaFind  www.melafind.com
MelaFind is the first and only medical device with FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union designed to assist dermatologists in the evaluation and diagnosis of melanoma at its most curable stage. The MelaFind system utilizes innovative software driven technology and state-of-the-art 3-D optical imaging to non-invasively extract data 2.5 mm below the skin surface from patient’s pigmented ambiguous moles and objectively analyzes them with proprietary algorithms. MelaFind provides important additional perspective to physicians via 3-D spectral images and 100% objective data analysis to help them better understand the structural disorganization of a patient’s pigmented ambiguous moles (before cutting the skin) during the evaluation and diagnosis process for melanoma.

About MELA Sciences, Inc.  www.melasciences.com
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as "seeks," "look forward," and "there seems" that suggest future events or trends. These statements, including our expectations regarding our ability to obtain a CPT code and appropriate reimbursement for our MelaFind system, are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company‘s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.

Media
Diana Garcia Redruello
MELA Sciences, Inc.
212-518-4226
dgarcia@melasciences.com

Investors
Andrew McDonald
LifeSci Advisors, LLC
646-597-6987

Press release via Mela Sciences.

Filed Under: Diagnostics, Medicare, News Well, Oncology Tagged With: MELA Sciences Inc., Press Release

In case you missed it

  • FDA clears Neurolief’s noninvasive neuromod tech to treat migraines
  • Could this hydrogel repair a broken heart?
  • Virta Health touts study of treatment preventing progression to Type 2 diabetes
  • Philips, DiA partner on AI-based applications for ultrasound
  • Cook Medical wins FDA breakthrough device designation for next-gen endovascular graft
  • FDA grants breakthrough nod to Anuncia’s cerebral spinal fluid treatment
  • Varian CEO Dow Wilson to retire after merger with Siemens Healthineers
  • Medtronic touts results of cardiac resynchronization therapy trial
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
  • Abbott researchers help discover a clue to an HIV cure
  • Q BioMed wins federal contract for bone cancer drug
  • Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
  • FDA accepts New Drug Application for Eyenovia pupil dilation tech
  • Axonics, Micro Systems Technologies partners to make rechargeable SNM device
  • Component Testing & Analysis: How to Gain Deeper Insights with a Universal Testing System
  • SeaSpine ticks up on 6.2% sales growth in Q4, reports losses
  • Boston Scientific completes Preventice buy, divests BTG Pharmaceutical business

RSS From Medical Design & Outsourcing

  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that they say could help repair and prevent further damage to the heart muscle after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]
  • Interpower debuts plugs in new colors
    Interpower announced that its NEMA 5-20 hospital-grade plugs for use in North America now come in molded colors of clear, black or gray on 10-foot lengths of flexible cord. These molded plugs complement the company’s NEMA 5-20 hand-wired hospital-grade plugs. The North American 18A hospital-grade power cord on 14 AWG SJT cable and North American… […]
  • Portescap motors gain certification
    Portescap announced that its slotless brushless DC motors for respirators have received ISO 13485:2016 certification. Expanding on ISO 9001, this standard contains specific requirements for parts traceability and risk management activities throughout the design and development stages. It also requires process and software validations at defined intervals. Independent risk management and quality compliance firm DNV… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS